phentermine has been researched along with Pregnancy in 16 studies
Phentermine: A central nervous system stimulant and sympathomimetic with actions and uses similar to those of DEXTROAMPHETAMINE. It has been used most frequently in the treatment of obesity.
Pregnancy: The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Food and Drug Administration approved phentermine-topiramate for obesity in 2012 and required a Risk Evaluation and Mitigation Strategy (REMS) to prevent prenatal exposure." | 8.31 | Assessment of the Risk Evaluation and Mitigation Strategy (REMS) for Phentermine-Topiramate to Prevent Exposure During Pregnancy. ( Brown, JD; Donahoo, WT; Hampp, C; Sarayani, A; Winterstein, AG, 2023) |
| "The US FDA required a Risk Evaluation and Mitigation Strategy (REMS) for phentermine/topiramate, an anti-obesity medication, to prevent congenital malformations." | 8.12 | Topiramate Utilization After Phentermine/Topiramate Approval for Obesity Management: Risk Minimization in the Era of Drug Repurposing. ( Brown, JD; Donahoo, WT; Hampp, C; Sarayani, A; Winterstein, AG, 2022) |
| " The objectives of our study are to describe weight loss, pregnancy rates, and live birth rates after short-term phentermine use in women with obesity and infertility." | 7.96 | A Retrospective Study Examining Phentermine on Preconception Weight Loss and Pregnancy Outcomes. ( Chang, JJ; Kim, SH; Lathi, RB, 2020) |
| "Controlled prospective cohort study comparing 98 women who had taken phentermine/fenfluramine to 233 women who had not, all of whom contacted the California Teratogen Information Service during pregnancy." | 7.71 | Pregnancy outcomes after first trimester exposure to phentermine/fenfluramine. ( Chambers, CD; Dick, LM; Felix, RJ; Johnson, KA; Jones, KL; Kao, KK, 2002) |
| " Food and Drug Administration approved phentermine-topiramate for obesity in 2012 and required a Risk Evaluation and Mitigation Strategy (REMS) to prevent prenatal exposure." | 4.31 | Assessment of the Risk Evaluation and Mitigation Strategy (REMS) for Phentermine-Topiramate to Prevent Exposure During Pregnancy. ( Brown, JD; Donahoo, WT; Hampp, C; Sarayani, A; Winterstein, AG, 2023) |
| "The US FDA required a Risk Evaluation and Mitigation Strategy (REMS) for phentermine/topiramate, an anti-obesity medication, to prevent congenital malformations." | 4.12 | Topiramate Utilization After Phentermine/Topiramate Approval for Obesity Management: Risk Minimization in the Era of Drug Repurposing. ( Brown, JD; Donahoo, WT; Hampp, C; Sarayani, A; Winterstein, AG, 2022) |
| " The objectives of our study are to describe weight loss, pregnancy rates, and live birth rates after short-term phentermine use in women with obesity and infertility." | 3.96 | A Retrospective Study Examining Phentermine on Preconception Weight Loss and Pregnancy Outcomes. ( Chang, JJ; Kim, SH; Lathi, RB, 2020) |
| "Controlled prospective cohort study comparing 98 women who had taken phentermine/fenfluramine to 233 women who had not, all of whom contacted the California Teratogen Information Service during pregnancy." | 3.71 | Pregnancy outcomes after first trimester exposure to phentermine/fenfluramine. ( Chambers, CD; Dick, LM; Felix, RJ; Johnson, KA; Jones, KL; Kao, KK, 2002) |
| "Pregnant rats were treated on Days 16-20 of pregnancy with 30 mg/kg chlorphentermine hydrochloride (CP) or an equal volume of 0." | 3.66 | Chlorphentermine-induced neonatal and maternal pulmonary phospholipidosis in rats. ( Reasor, MJ; Thoma-Laurie, DL; Walker, ER, 1983) |
| "The cornerstones of treatment for obesity, and even more so for simple overweight, are dietary measures and physical exercise." | 1.39 | Topiramate + phentermine. An excessively dangerous appetite-suppressant combination. ( , 2013) |
| "Weight loss during pregnancy is therefore considered a risk factor." | 1.38 | Appetite suppressants in pregnancy. ( Hubičková Heringová, L; Kralova, T; Manakova, E, 2012) |
| "In addition to the phospholipidosis in utero, drug exposure results in toxicity to the offspring; newborn rats die within 48 h of birth." | 1.27 | Newborn response to cationic amphiphilic drugs. ( Kacew, S; Reasor, MJ, 1985) |
| "Generalized lipidosis was found in the offspring of both species, albeit of lesser degree than in the mothers." | 1.26 | Generalized lipidosis in newborn rats and Guinea pigs induced during prenatal development by administration of amphiphilic drugs to pregnant animals. ( Lüllmann-Rauch, R; Stoermer, B, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (37.50) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 1 (6.25) | 29.6817 |
| 2010's | 5 (31.25) | 24.3611 |
| 2020's | 3 (18.75) | 2.80 |
| Authors | Studies |
|---|---|
| Sarayani, A | 2 |
| Hampp, C | 2 |
| Brown, JD | 2 |
| Donahoo, WT | 2 |
| Winterstein, AG | 2 |
| Chang, JJ | 1 |
| Lathi, RB | 1 |
| Kim, SH | 1 |
| Bello, NT | 1 |
| Campbell, SC | 1 |
| Colman, E | 1 |
| Golden, J | 1 |
| Roberts, M | 1 |
| Egan, A | 1 |
| Weaver, J | 1 |
| Rosebraugh, C | 1 |
| Manakova, E | 1 |
| Kralova, T | 1 |
| Hubičková Heringová, L | 1 |
| Zarin, DA | 1 |
| Tse, T | 1 |
| Lüllmann-Rauch, R | 1 |
| Stoermer, B | 1 |
| Thoma-Laurie, DL | 1 |
| Walker, ER | 2 |
| Reasor, MJ | 3 |
| Thoma-Laurie, D | 1 |
| Bratter, J | 1 |
| Gessner, IH | 1 |
| Rowland, NE | 1 |
| Jones, KL | 1 |
| Johnson, KA | 1 |
| Dick, LM | 1 |
| Felix, RJ | 1 |
| Kao, KK | 1 |
| Chambers, CD | 1 |
| Kacew, S | 2 |
| Dubas, TC | 1 |
| Stevenson, AJ | 1 |
| Rzeszowska, G | 1 |
| Ciszewska-Popiolek, B | 1 |
| Romanowska-Sarlej, J | 1 |
16 other studies available for phentermine and Pregnancy
| Article | Year |
|---|---|
Topiramate Utilization After Phentermine/Topiramate Approval for Obesity Management: Risk Minimization in the Era of Drug Repurposing.
Topics: Anti-Obesity Agents; Atorvastatin; Drug Approval; Drug Repositioning; Female; Fructose; Humans; Male | 2022 |
Assessment of the Risk Evaluation and Mitigation Strategy (REMS) for Phentermine-Topiramate to Prevent Exposure During Pregnancy.
Topics: Anti-Obesity Agents; Contraceptive Agents; Female; Fructose; Humans; Obesity; Phentermine; Pregnancy | 2023 |
A Retrospective Study Examining Phentermine on Preconception Weight Loss and Pregnancy Outcomes.
Topics: Adolescent; Adult; Anti-Obesity Agents; Female; Humans; Middle Aged; Phentermine; Pregnancy; Pregnan | 2020 |
Topiramate + phentermine. An excessively dangerous appetite-suppressant combination.
Topics: Anti-Obesity Agents; Appetite Depressants; Drug Approval; Drug Combinations; European Union; Female; | 2013 |
Two anti-obesity hopefuls and their safety.
Topics: Adult; Anti-Obesity Agents; Benzazepines; Dose-Response Relationship, Drug; Drug Combinations; Drugs | 2012 |
The FDA's assessment of two drugs for chronic weight management.
Topics: Abnormalities, Drug-Induced; Anti-Obesity Agents; Benzazepines; Delayed-Action Preparations; Drug Ap | 2012 |
Appetite suppressants in pregnancy.
Topics: Abnormalities, Multiple; Abortion, Spontaneous; Appetite Depressants; Cyclobutanes; Czech Republic; | 2012 |
Unambiguous identification of obesity trials.
Topics: Anti-Obesity Agents; Benzazepines; Drug Approval; Female; Fructose; Humans; Obesity; Phentermine; Pr | 2013 |
Generalized lipidosis in newborn rats and Guinea pigs induced during prenatal development by administration of amphiphilic drugs to pregnant animals.
Topics: Adrenal Glands; Animals; Chloroquine; Chlorphentermine; Female; Guinea Pigs; Hypothalamus; Kidney; L | 1982 |
Chlorphentermine-induced neonatal and maternal pulmonary phospholipidosis in rats.
Topics: Animals; Chlorphentermine; Female; Lung; Macrophages; Microscopy, Electron; Phentermine; Phospholipi | 1983 |
Neonatal toxicity in rats following in utero exposure to chlorphentermine or phentermine.
Topics: Animals; Animals, Newborn; Body Weight; Chlorphentermine; Female; Lung; Lung Diseases; Maternal-Feta | 1982 |
Effects of prenatal co-administration of phentermine and dexfenfluramine in rats.
Topics: Animals; Appetite Depressants; Axons; Dexfenfluramine; Drug Combinations; Female; Fetus; Hippocampus | 1999 |
Pregnancy outcomes after first trimester exposure to phentermine/fenfluramine.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Appetite Depressants; Cohort Studies; Drug Thera | 2002 |
Renal and hepatic nucleic acid metabolism in neonates: relation to experimental duration, chlorphentermine dose as well as subsequent withdrawal.
Topics: Animals; Animals, Newborn; Chlorphentermine; DNA; Dose-Response Relationship, Drug; Female; Humans; | 1978 |
Newborn response to cationic amphiphilic drugs.
Topics: Animals; Animals, Newborn; Chlorphentermine; Dexamethasone; Drug Interactions; Female; Fetus; Gentam | 1985 |
[The influence of avipron administered during pregnancy on the placenta and some organs of the mother and foetus in the light of histochemical research (author's transl)].
Topics: Adenosine Triphosphatases; Animals; Chlorphentermine; Drug Evaluation, Preclinical; Female; Fetus; H | 1974 |